Wallax Augusto Silva Ferreira

Dr. Wallax Augusto Silva Ferreira

Instituto Evandro Chagas, Ananindeua, Brazil
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
GKGabriela Sarti Kinker
Gabriela Sarti Kinker
GVGlauco Akelinghton Freire Vitiello
Glauco Akelinghton Freire Vitiello
WFWallax Augusto Silva Ferreira
Wallax Augusto Silva Ferreira
ACAlexandre Silva Chaves
Alexandre Silva Chaves
VLVladmir Cláudio Cordeiro de Lima
Vladmir Cláudio Cordeiro de Lima
TMTiago Medina
Tiago Medina
The immune system plays a crucial role in cancer development either by fostering tumor growth or destroying tumor cells, which has open new avenues for cancer immunotherapy. It was only over the last decade that the role of B cells in controlling anti-tumor immune responses in the tumor milieu has begun to be appreciated. B and plasma cells can exert anti-tumor effects through antibody-dependent cell cytotoxicity (ADCC) and activation of the complement cascade, even though their effector functions extend beyond the classical humoral immunity. In tumor tissues, B cells can be found in lymphoid aggregates, known as tertiary lymphoid structures (TLSs), well-organized non-encapsulated structures composed of immune and stromal cells. These structures reflect a process of lymphoid neogenesis occurring in peripheral tissues upon long-lasting exposure to inflammatory signals. The TLS provides an area of intense B cell antigen presentation that can lead to optimal T cell activation and effector functions, as well as the generation of effector B cells, which can be further differentiated in either antibody-secreting plasma cells or memory B cells. Of clinical interest, the crosstalk between B cells and antigen-experienced and exhausted CD8+T cells within mature TLS was recently associated with improved response to immune checkpoint blockade (ICB) in melanoma, sarcoma and lung cancer. Otherwise, B cells sparsely distributed in the tumor microenvironment or organized in immature TLSs were found to exert immune-regulatory functions, inhibiting anti-tumor immunity through the secretion of anti-inflammatory cytokines. Such phenotype might arise when B cells interact with malignant cells rather than T and dendritic cells. Differences in the spatial distribution likely underlie discrepancies between the role of B cells inferred from human samples or mouse models. Many fast-growing orthotopic tumors develop a malignant cell-rich bulk with reduced stroma and are devoid of TLSs, which highlights the importance of carefully selecting pre-clinical models. In summary, strategies that promote TLS formation in close proximity to tumor cells are likely to favor immunotherapy responses. Here, the cellular and molecular programs coordinating B cell development, activation and organization within TLSs will be reviewed, focusing on their translational relevance to cancer immunotherapy.

30 August 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
FLFrancisco Canindé Ferreira de Luna
Francisco Canindé Ferreira de Luna
WFWallax Augusto Silva Ferreira
Wallax Augusto Silva Ferreira
SCSamir Mansour Moraes Casseb
Samir Mansour Moraes Casseb
Edivaldo HERCULANO CORREA de OliveiraEdivaldo HERCULANO CORREA de Oliveira
Edivaldo HERCULANO CORREA de Oliveira
Natural compounds with pharmacological activity, flavonoids have been the subject of an exponential increase in studies in the field of scientific research focused on therapeutic purposes due to their bioactive properties, such as antioxidant, anti-inflammatory, anti-aging, antibacterial, antiviral, neuroprotective, radioprotective, and antitumor activities. The biological potential of flavonoids, added to their bioavailability, cost-effectiveness, and minimal side effects, direct them as promising cytotoxic anticancer compounds in the optimization of therapies and the search for new drugs in the treatment of cancer, since some extensively antineoplastic therapeutic approaches have become less effective due to tumor resistance to drugs commonly used in chemotherapy. In this review, we emphasize the antitumor properties of tangeretin, a flavonoid found in citrus fruits that has shown activity against some hallmarks of cancer in several types of cancerous cell lines, such as antiproliferative, apoptotic, anti-inflammatory, anti-metastatic, anti-angiogenic, antioxidant, regulatory expression of tumor-suppressor genes, and epigenetic modulation.

2 December 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
GVGlauco Akelinghton Freire Vitiello
Glauco Akelinghton Freire Vitiello
WFWallax Augusto Silva Ferreira
Wallax Augusto Silva Ferreira
VLVladmir Cláudio Cordeiro de Lima
Vladmir Cláudio Cordeiro de Lima
TMTiago Medina
Tiago Medina
In recent years, it became apparent that cancers either associated with viral infections or aberrantly expressing endogenous retroviral elements (EREs) are more immunogenic, exhibiting an intense intra-tumor immune cell infiltration characterized by a robust cytolytic apparatus. On the other hand, epigenetic regulation of EREs is crucial to maintain steady-state conditions and cell homeostasis. In line with this, epigenetic disruptions within steady-state cells can lead to cancer development and trigger the release of EREs into the cytoplasmic compartment. As such, detection of viral molecules by intracellular innate immune sensors leads to the production of type I and type III interferons that act to induce an antiviral state, thus restraining viral replication. This knowledge has recently gained momentum due to the possibility of triggering intratumoral activation of interferon responses, which could be used as an adjuvant to elicit strong anti-tumor immune responses that ultimately lead to a cascade of cytokine production. Accordingly, several therapeutic approaches are currently being tested using this rationale to improve responses to cancer immunotherapies. In this review, we discuss the immune mechanisms operating in viral infections, show evidence that exogenous viruses and endogenous retroviruses in cancer may enhance tumor immunogenicity, dissect the epigenetic control of EREs, and point to interferon pathway activation in the tumor milieu as a promising molecular predictive marker and immunotherapy target. Finally, we briefly discuss current strategies to modulate these responses within tumor tissues, including the clinical use of innate immune receptor agonists and DNA demethylating agents.

Verified
Journal Article
Open access
PDF file
IPIgor Pessôa
Igor Pessôa
CACarolina Koury Amorim
Carolina Koury Amorim
WFWallax Augusto Silva Ferreira
Wallax Augusto Silva Ferreira
FSFERNANDA SAGICA
FERNANDA SAGICA
JBJosé Reginaldo Brito
José Reginaldo Brito
Edivaldo HERCULANO CORREA de OliveiraEdivaldo HERCULANO CORREA de Oliveira
Edivaldo HERCULANO CORREA de Oliveira
Gliomas are the most frequent primary tumors of central nervous system and represent a heterogeneous group of tumors that originates from the glial cells. TP53, PTEN, and CDKN2A are important tumor suppressor genes that encode proteins involved in sustaining cellular homeostasis by different signaling pathways. Though genetic alterations in these genes play a significant role in tumorigenesis, few studies are available regarding the incidence and relation of concomitant TP53, PTEN, and CDKN2A alterations in gliomas. The purpose of this study was to evaluate the occurrence of mutation and deletion in these genes, through single-strand conformational polymorphism, array-comparative genomic hybridization, and fluorescence in situ hybridization techniques, in 69 gliomas samples. Molecular results demonstrated a significant higher prevalence of TP53, PTEN, and CDKN2A alterations in astrocytoma than other tumor subtypes, and heterozygous deletion was the most frequent event. In addition, a significant association was observed between TP53 and CDKN2A alterations (p = 0.0424), which tend to coexist in low grade astrocytomas (5/46 cases (10.9%)), suggesting that they are early events in development of these tumors, and PTEN and CDKN2A deletions (p = 0.0022), which occurred concomitantly in 9/50 (18%) patients, with CDKN2A changes preceding PTEN deletions, present preferably in high-grade gliomas.

1 January 2015 in Molecular Phylogenetics and Evolution
Verified
Journal Article
Closed access
MMMichelle P. Mercês
Michelle P. Mercês
JAJessica W. Lynch Alfaro
Jessica W. Lynch Alfaro
WFWallax Augusto Silva Ferreira
Wallax Augusto Silva Ferreira
MHMaria L. Harada
Maria L. Harada
JJJosé S. Silva Júnior
José S. Silva Júnior

1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
DPDanilo Do Rosário Pinheiro
Danilo Do Rosário Pinheiro
WFWallax Augusto Silva Ferreira
Wallax Augusto Silva Ferreira
MBMariceli Baia Leão Barros
Mariceli Baia Leão Barros
MAMariana Diniz Araújo
Mariana Diniz Araújo
SRSymara Rodrigues-Antunes
Symara Rodrigues-Antunes
BBBarbara Borges
Barbara Borges
Gastric cancer is considered one of the most deadly tumors worldwide. Even with the decline in its incidence, the mortality rate of this disease has remained high, mainly due to its late diagnosis and to the lack of precise prognostic markers. The main purpose of this review is to present genetic, epigenetic and proteomic molecular markers that may be used in a diagnostic and prognostic manner and to discuss the pros and cons of each type of marker for improving clinical practice. In this sense, we observed that the use of genetic markers, especially mutations and polymorphisms, should be carefully considered, as they are strongly affected by ethnicity. Proteomic-based markers show promise, but the higher costs of the associated techniques continue to make this approach expensive for routine use. Alternatively, epigenetic markers appear to be very promising, as they can be detected in bodily fluids as well as tissues. However, such markers must be used carefully because epigenetic changes may occur due to environmental factors and aging. Despite the advances in technology and its access, to date, there are few defined biomarkers of prognostic and diagnostic use for gastric tumors. Therefore, the use of a panel of several approaches (genetic, epigenetic and proteomic) should be considered the best alternative for clinical practice.